Protalex, Inc. Announces Presentation Of Preclinical Data With PRTX-100 Supporting Treatment Of Immune Thrombocytopenia At The American Society of Hematology 57th Annual Meeting And Exposition

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting preclinical results from a study of Staphylococcal protein A (PRTX-100) for the treatment of Immune Thrombocytopenia (ITP) will be presented at the upcoming American Society of Hematology (ASH) 57th Annual Meeting and Exposition being held in Orlando, Florida from December 5-8, 2015. The abstract is available on the ASH website at http://www.hematology.org and on the Company’s website at www.protalex.com.

Help employers find you! Check out all the jobs and post your resume.